Company news

Share this article:

Eisai hosted a dedication ceremony to commemorate the opening of its newly constructed US corporate headquarters in Woodcliff Lake, NJ. The three-story facility will provide Eisai with 209,000 square feet of space and capacity for more than 700 people to accommodate its ongoing expansion and anticipated future growth. The dedication ceremony was attended by Eisai executives and state and local dignitaries, including Soichi Matsuno, deputy president and executive officer, Eisai; Hajime Shimizu, president, Eisai Corporation of North America and chairman and CEO; and Lonnel Coats, President & COO, Eisai. Other notable guests included New Jersey Governor Jon Corzine, and Billy Tauzin, president and CEO of the Pharmaceutical Research and Manufacturers of America.

Novavax has agreed with Allergan to terminate its manufacturing supply agreement for Estrasorb. The drug was previously licensed by Novavax to Esprit Pharma (recently acquired by Allergan, Inc.) in 2006 and is an approved estrogen product for relief of moderate to severe vasomotor symptoms (hot flashes) associated with menopause. Under the termination agreement, Novavax will complete the manufacture of remaining orders for the product and plans to close its Philadelphia manufacturing facility over the next few months. Allergan will continue to sell Estrasorb for the foreseeable future from available inventory. Additionally, Allergan will return to Novavax the rights to develop ESP 210, an investigational drug in Phase II development for the treatment of hypoactive sexual desire disorder.

Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.